%PDF-1.3
%
3 0 obj
<>>>/BBox[0 0 612 792]/Length 144>>stream
x wF@ع?n悊
E)]%n4G9GrBR=|r֫IO2^jFۙ3ꮢk/H)QkþƁ7B4Qt>`-KE4r؏GS?t/
endstream
endobj
7 0 obj
<>>>/BBox[0 0 612 792]/Length 144>>stream
x wF@ع?n悊
E)]%n4G9GrBR=|r֫IO2^jFۙ3ꮢk/H)QkþƁ7B4Qt>`-KE4r؏GS?t/
endstream
endobj
6 0 obj
<>>>/BBox[0 0 612 792]/Length 144>>stream
x wF@ع?n悊
E)]%n4G9GrBR=|r֫IO2^jFۙ3ꮢk/H)QkþƁ7B4Qt>`-KE4r؏GS?t/
endstream
endobj
4 0 obj
<>>>/BBox[0 0 612 792]/Length 144>>stream
x wF@ع?n悊
E)]%n4G9GrBR=|r֫IO2^jFۙ3ꮢk/H)QkþƁ7B4Qt>`-KE4r؏GS?t/
endstream
endobj
8 0 obj
<>>>/BBox[0 0 612 792]/Length 144>>stream
x wF@ع?n悊
E)]%n4G9GrBR=|r֫IO2^jFۙ3ꮢk/H)QkþƁ7B4Qt>`-KE4r؏GS?t/
endstream
endobj
1 0 obj
<>>>/BBox[0 0 612 792]/Length 144>>stream
x wF@ع?n悊
E)]%n4G9GrBR=|r֫IO2^jFۙ3ꮢk/H)QkþƁ7B4Qt>`-KE4r؏GS?t/
endstream
endobj
5 0 obj
<>>>/BBox[0 0 612 792]/Length 144>>stream
x wF@ع?n悊
E)]%n4G9GrBR=|r֫IO2^jFۙ3ꮢk/H)QkþƁ7B4Qt>`-KE4r؏GS?t/
endstream
endobj
10 0 obj
<>stream
Acrobat Distiller 8.1.0 (Windows); modified using iText 4.2.0 by 1T3XT
Arbortext Advanced Print Publisher 9.0.114/W
2020-01-22T00:11:16-08:00
2020-01-14T03:58:51+05:30
application/pdf
JOP-2019-0051-ver9-Zandi_2P 1..7
uuid:08fd0e19-0a7d-4d73-8360-556e559618dc
uuid:e04ca6bb-e82c-420c-b663-6caeffb5057d
endstream
endobj
11 0 obj
<>stream
x+ |
endstream
endobj
12 0 obj
<>stream
xS**T0T0 Bi yA$
endstream
endobj
13 0 obj
<>stream
x+ |
endstream
endobj
14 0 obj
<>stream
xS**T0T0 Bi y8#
endstream
endobj
15 0 obj
<>stream
x+ |
endstream
endobj
16 0 obj
<>stream
xS**T0T0 Bi yJ%
endstream
endobj
17 0 obj
<>stream
x+ |
endstream
endobj
18 0 obj
<>stream
xS**T0T0 Bi yS&
endstream
endobj
19 0 obj
<>stream
x+ |
endstream
endobj
20 0 obj
<>stream
xS**T0T0 Bi ye(
endstream
endobj
21 0 obj
<>stream
x+ |
endstream
endobj
22 0 obj
<>stream
xS**T0T0 Bi yn)
endstream
endobj
23 0 obj
<>stream
x+ |
endstream
endobj
24 0 obj
<>stream
xS**T0T0 Bi y\'
endstream
endobj
26 0 obj
<>stream
/GS1 gs
BT
/F5 1 Tf
9.843 0 0 9.843 62.022 725.1588 Tm
0 0 0 rg
.012 Tc
0 Tw
[(ocri)5(pl)5(asmin)-352(o)-.6(r)-351.9(v)-.6(i)5(t)-.7(rect)5(omy)-357.7(a)4(re)-353.1(co)5.1(ns)5.3(idered.)-354.3(T)4(he)-353.1(pu)5.1(rp)5.1(ose)-353.1(o)-.6(f)]TJ
0 -1.1174 TD
.0122 Tc
[(th)5.3(er)5.4(ap)5.3(y)-282.6(i)-.5(s)-276.7(t)-.5(o)-276.9(r)-.4(elease)-278(vi)5.2(tr)5.4(eou)5.3(s)-282.4(t)5.2(r)-.4(acti)5.2(on)-276.9(on)-276.9(th)5.3(e)-283.8(m)4.1(acul)5.2(a)-283.8(b)-.4(efo)5.3(r)-.4(e)]TJ
0 -1.1116 TD
.012 Tc
[(th)5.1(e)-272.5(o)5.1(ccur)5.2(ren)5.1(c)-1.8(e)-266.7(o)-.6(f)-265.5(i)-.7(r)5.2(r)-.6(eversi)5(bl)5(e)-272.5(s)5.3(tru)5.1(c)-1.8(t)5(u)-.6(r)5.2(a)-1.8(l)-265.7(r)-.6(et)5(in)5.1(al)-265.7(damage.)]TJ
1.0137 -1.1116 TD
.0189 Tc
[(Substanc)5.1(es)-367.9(that)-362.5(are)-369.3(d).5(irecte)5.1(d)-368.1(against)-362.5(b).5(iochemica)5.1(l)-368.2(com-)]TJ
-1.0137 -1.1116 TD
.0187 Tc
[(ponents)-466(o).3(f)-471.9(t).2(he)-467.4(vitreomacular)-466.2(i).2(nterface,)-468.5(includi)6(ng)-472(chon-)]TJ
0 -1.1174 TD
[(droitinase,)-169.1(dispase,)-169.1(and)-172.6(hyaluronidase,)-169.1(h).2(ave)-173.7(b).2(een)-172.6(t).1(ested)-172.6(but)]TJ
0 -1.1116 TD
[(were)-236.9(abandoned)-235.7(due)-236.9(to)-235.7(insufcient)-235.9(c)-.7(linical)-235.9(efcacy)-235.7(and/or)]TJ
T*
.0183 Tc
(complications.)Tj
7.3823 0 0 6.5614 122.4566 652.8187 Tm
.0222 Tc
[(3)-7.7(5)]TJ
9.843 0 0 9.843 72 637.455 Tm
0 Tc
[(Ocriplasmin,)-417.6(a)-411.2(serine)-417.8(protease,)-413.1(enzymatic)-10.3(ally)-409(induces)-418.9(a)]TJ
-1.0137 -1.1116 TD
[()50.8(pharmacological)-278.4(vitreolysis)48.9()-271.8(a)0(s)-268.1(i)0(t)-267.4(breaks)-273.7(down)-264.5(bronectin)]TJ
T*
[(and)-304(laminin)-304.2(at)-303(the)-304.1(pathological)-305.2(vitreoretinal)-306.4(interface.)]TJ
7.3823 0 0 6.5614 278.0787 619.9368 Tm
(6)Tj
9.843 0 0 9.843 284.7117 615.5715 Tm
(Pre-)Tj
-22.6241 -1.1174 TD
[(clinical)-490.9(and)-488.3(clinical)-496.6(studies)-486.8(have)-490.5(demonstrated)-490.3(that)-489.6(ocri-)]TJ
0 -1.1116 TD
[(plasmin)-217.5(can)-213(induce)-216.4(vitreous)-211.6(liquefaction)-218.8(and)-211.8(separation)-216.1(from)]TJ
T*
[(the)-269.5(retina.)]TJ
7.3823 0 0 6.5614 101.8204 587.0549 Tm
(713)Tj
9.843 0 0 9.843 72 571.7479 Tm
.0117 Tc
[(Recen)4.8(tly)4.8(,)-343.1(s)-.7(u)4.8(b)-.9(r)4.9(e)-2.1(ti)4.7(nal)-346.6(d)4.8(ep)4.8(os)5(its)-340.5(and)-340.7()-.8(ui)4.7(d,)-343.1(as)-346.3(wel)4.7(l)-346.6(as)-340.5(out)4.7(er)]TJ
-1.0137 -1.1174 TD
.0131 Tc
[(se)5.1(gm)5(en)6.2(t)-304.9(c)-.7(h)6.2(a)-.7(n)6.2(g).5(e)5.1(s).7(,)-301.4(h).5(a)5.1(v).5(e)-300.2(b).5(ee)5.1(n)-304.8(r)6.3(ep)6.2(ort)6.1(ed)-299(af)6.3(ter)-299(o).5(c)5.1(r).5(ip)6.2(la)5.1(sm)5(in)-304.8(i)6.1(n).5(-)]TJ
0 -1.1116 TD
.012 Tc
[(ject)5(io)5.1(ns)-530.3(by)-530.5(s)5.3(e)-1.8(veral)-530.6(g)-.6(r)5.2(oup)5.1(s.)]TJ
7.3823 0 0 6.5614 177.959 554.1731 Tm
.0145 Tc
(1420)Tj
9.843 0 0 9.843 202.1669 549.8077 Tm
.012 Tc
[(It)-530.6(is)5.3(,)-532.8(h)5.1(owever,)-527.1(not)-530.6(y)5.1(e)-1.8(t)]TJ
-14.238 -1.1116 TD
.0124 Tc
[(kn)5.5(own)-184.5(h)5.5(ow)-179.6(th)5.5(os)5.7(e)-185.7(a)4.4(ffect)-178.9(lo)5.5(ng)5.5(-t)5.4(erm)-180(v)5.5(is)5.7(ual)-178.9(a)4.4(cui)5.4(t)-.3(y)-178.8(a)-1.4(n)5.5(d)-178.8(wheth)5.5(e)-1.4(r)]TJ
0 -1.1174 TD
.0119 Tc
[(th)5(e)-284.1(r)5.1(ep)5(or)5.1(ted)-282.9(s)5.2(ubr)5.1(et)4.9(in)5(al)-277.3(depos)5.2(it)4.9(s)-282.7(a)3.9(re)-278.3(resor)5.1(b)-.7(ed)-282.9(aft)4.9(e)-1.9(r)-277.1(a)-278.3(certain)]TJ
0 -1.1116 TD
.0121 Tc
[(amou)5.2(nt)-265.6(of)-265.4(ti)5.1(me.)]TJ
1.0137 -1.1116 TD
0 Tc
[(In)-290.1(this)-286.7(retrospective)-295.6(observational)-294.4(case)-289.9(series,)-288.5(51)-290.2(patients)]TJ
-1.0137 -1.1174 TD
[(with)-172.6(symptomatic)-178.4(VMT)-173.3(were)-174.6(treated)-172.7(with)-172.6(a)-175(single)-174.9(intravitreal)]TJ
0 -1.1116 TD
[(ocriplasmin)-275(injection)-277.7(\(IOI\))-271.2(between)-277.1(February)-275.9(2014)-275.1(and)-269.4(July)]TJ
T*
[(2018)-188.7(and)-183(followed)-189.6(up)-186.5(for)-181.8(648)-188.7(months.)-184(VMT)-190.6(release)-185.1(and)-188.8(MH)]TJ
0 -1.1174 TD
[(closure)-378.6(rates,)-374(visual)-376.5(acuity)-377.8(changes,)-371.5(and)-378.8(subretinal)-376.4(deposit)]TJ
0 -1.1116 TD
[(resolution,)-263.4(as)-256.6(well)-260.1(as)-256.6(its)-256.8(effect)-263.6(on)-255.6(visual)-261.3(acuity)-256.9(and)-257.9(potential)]TJ
T*
[(risk)-177.1(factors)-171.2(for)-176(its)-176.2(development,)-176.1(were)-174.6(examined)-174.9(and)-177.3(analyzed.)]TJ
/F3 1 Tf
9.9626 0 0 9.9626 62.022 414.1416 Tm
(Methods)Tj
/F5 1 Tf
9.843 0 0 9.843 72 396.2834 Tm
[(The)-368.5(study)-368.3(was)-368(approved)-368.2(by)-365.1(the)-367.5(local)-371(institutional)-373.3(ethics)]TJ
-1.0137 -1.1116 TD
[(committees)-339.7(in)-330.6(Bern)-334.9(\(Kantonale)-338.1(Ethikkommission)-337.1(Bern)-334.9(and)]TJ
T*
[(Zuerich,)-325.8(reference)-332.4(No.)-323.3(2016-02084\).)-326.5(Informed)-327.9(consent)-326.8(was)]TJ
0 -1.1174 TD
[(obtained)-264.8(from)-259(each)-261.3(participant)-269.5(in)-255.8(accordance)-271.4(with)-259(the)-263.8(tenets)]TJ
0 -1.1116 TD
[(of)-336.2(the)-332.9(declaration)-339.7(of)-330.5(Helsinki.)]TJ
1.0137 -1.1116 TD
[(Patients)-310.7(were)-307.1(included)-310.9(in)-307.6(the)-309.9(series)-313.9(if)-307.6(they)-305.2(had)-309.7(persistent)]TJ
-1.0137 -1.1174 TD
(\()Tj
/F6 1 Tf
.3341 0 TD
(>)Tj
/F5 1 Tf
.5529 0 TD
[(3)-456.1(months\))-463.9(and)-459.5(symptomatic)-466.4(VMT)-461.3(without)-458.2(spontaneous)]TJ
-.887 -1.1116 TD
[(release)-507.6(and)-499.8(an)-498.7(adhesion)-500.7(size)]TJ
/F6 1 Tf
12.8153 0 TD
(<)Tj
/F5 1 Tf
.5472 0 TD
(1,500)Tj
/F7 1 Tf
2.4191 0 TD
(m)Tj
/F5 1 Tf
.5529 0 TD
[(m)-497.7(with)-500.9(or)-503.3(without)]TJ
-16.3345 -1.1116 TD
[(concomitant)-316.7(FTMH)-312.5(\(with)-311.9(a)-313.3(maximum)-312.2(size)-311.9(of)-313.2(400)]TJ
/F7 1 Tf
20.614 0 TD
(m)Tj
/F5 1 Tf
.5529 0 TD
[(m\).)-312.1(Ex-)]TJ
-21.1669 -1.1116 TD
[(clusion)-308.4(criteria)-306.4(included)-305.1(coexistence)-306(of)-307.4(any)-304(foveal)-302.8(or)-307.4(extra-)]TJ
0 -1.1174 TD
[(foveal)-325.8(epiretinal)-326(membrane)-325.8(\(ERM\),)-328.8(clinically)-326.2(insufciently)]TJ
0 -1.1116 TD
[(controlled)-422.6(glaucoma,)-426(structural)-428.2(damage)-420.3(to)-422.8(the)-419.3(macula)-426.2(ex-)]TJ
T*
[(cluding)-199.2(functional)-198(gain,)-193.4(retinal)-200.5(detachment,)-199.1(and)-194.5(any)-194.5(systemic)]TJ
0 -1.1174 TD
[(disease)-489(interfering)-492.8(with)-489.3(the)-482.6(local)-491.9(situation)-489.5(\(i.e.,)-487.2(systemic)]TJ
0 -1.1116 TD
[(vasculitis\),)-259.9(and)-257.9(any)-252.1(diabetic)-260.4(retinopathy.)-260.1(All)-257.9(eyes)-254.2(received)-261.2(1)]TJ
T*
[(single)-278.5(injection)-271.9(of)-278.6(0.125)-163.4(mg)-274.1(ocriplasmin)-280.8(\()-122(Jetrea)]TJ
/F6 1 Tf
7.3823 0 0 6.5614 252.5669 236.296 Tm
()Tj
/F5 1 Tf
9.843 0 0 9.843 261.1275 231.9306 Tm
(Thrombo-)Tj
-20.2281 -1.1174 TD
[(Genics;)-322(Alcon/Novartis,)-317(EU\))-316.4(under)-317.7(sterile)-321.2(conditions)-317.6(in)-313.3(ac-)]TJ
0 -1.1116 TD
[(cordance)-272.6(with)-276.2(local)-273(standard)-270.2(procedures.)]TJ
1.0137 -1.1116 TD
[(The)-287.9(primary)-292.4(endpoint)-292.5(was)-293.1(anatomical)-293.8(success,)-296.3(dened)-291(as)]TJ
-1.0137 -1.1174 TD
[(complete)-336.3(VMT)-334.6(release)-340.6(and/or)-336.2(MH)-332.3(closure.)]TJ
1.0137 -1.1116 TD
[(Secondary)-479.7(endpoints)-477.7(included)-477.9(change)-482.4(in)-474.6(best-corrected)]TJ
-1.0137 -1.1116 TD
[(visual)-318.9(acuity)-314.5(\(BCVA\))-315.6(from)-316.6(before)-314.1(to)-313.3(up)-313.2(to)-313.4(24)-313.2(months)-313(after)]TJ
T*
[(Jetrea)-539.9(injection,)-540.3(and)-534.4(development)-541.2(and)-534.4(evolution)-541.4(of)-532.1(sub-)]TJ
0 -1.1174 TD
[(retinal)-557.6(deposits)-557(visible)-556.2(in)-549.5(optical)-557.6(coherence)-557.1(tomography)]TJ
0 -1.1116 TD
[(\(OCT\))-336.9(in)-330.6(response)-339(to)-330.6(treatment.)]TJ
1.0137 -1.1116 TD
[(Al)19.8(l)-352.6(p)0(a)19.7(t)0(i)20.6(e)0(n)19.7(t)0(s)-342(w)0(i)14.1(t)0(h)-342.1(a)-347.8(pe)19.7(rs)15.3(is)20.9(te)19.6(nt)-342.1(an)19.7(d)-352.4(s)0(y)21(m)0(p)19.6(t)0(o)15(m)0(a)18.4(t)0(i)20.6(c)-353.6(VM)19.1(T)-347.9(t)0(h)15(a)0(t)]TJ
-1.0137 -1.1174 TD
[(fu)20.9(l)15.1(ll)20.6(ed)-193.4(th)15(e)-203.8(i)0(n)20.7(c)0(l)19.5(u)0(s)15.3(i)0(o)20.7(n)-202.7(cr)19.7(it)14.8(er)19.7(ia)-193.6(\(a)14(dh)20.8(es)19.9(io)20.7(n)-208.4(s)0(i)20.9(z)0(e)]TJ
/F6 1 Tf
17.2849 0 TD
(<)Tj
/F5 1 Tf
.5414 0 TD
[(1,)24.3(50)15.1(0)]TJ
/F7 1 Tf
2.3672 0 TD
(m)Tj
/F5 1 Tf
.5414 0 TD
.2039 Tc
[(ma)203.9(n)223.6(d)-4.5(a)203.9(n)]TJ
-20.7349 -1.1116 TD
0 Tc
[(MH)-199.8(si)20.9(ze)]TJ
/F6 1 Tf
3.5422 0 TD
(<)Tj
/F5 1 Tf
.5414 0 TD
[(40)20.8(0)]TJ
/F7 1 Tf
1.6358 0 TD
(m)Tj
/F5 1 Tf
.5414 0 TD
[(m,)-201.6(no)-198(ER)18.6(M\))-198.9(we)18.8(re)19.7(,)-205(t)0(h)20.7(u)0(s)15.3(,)-205(el)19.5(ig)20.7(ib)15(le)-199.3(fo)20.9(r)-208.4(t)0(r)20.7(e)0(a)18.5(t)0(m)19.5(e)0(n)19.7(t)0(.)]TJ
-5.2471 -1.1116 TD
[(Based)-486.7(on)-480.3(a)-480.3(success)-488.7(rate)-484.9(of)-480.2(50%,)-485.9(they)-478(were)-485.6(given)-484.9(the)]TJ
-1.0137 -1.1174 TD
[(choice)-511.3(of)-503.3(the)-511.4(following)-506.5(options:)-510.1(treatment)-510.3(with)-506.6(a)-509.1(single)]TJ
0 -1.1116 TD
[(intravitreal)-362.9(injection)-358.3(of)-353.5(ocriplasmin;)-362.7(or)-353.5(surgery)-360(\(pars)-357.7(plana)]TJ
T*
[(vitrectomy)-464.2([PPV])]TJ
/F6 1 Tf
7.4761 0 TD
()Tj
/F5 1 Tf
.7142 0 TD
[(cataract)-469.9(surgery\).)-462.4(Patient)-465.3(selection)-468.6(for)]TJ
-8.1903 -1.1174 TD
[(an)-377.7(IOI)-378.5(treatment)-383.6(was)-379.5(the)-379(same)-376.4(as)-377.5(for)-377.6(vitrectomy)-383.6(provided)]TJ
25.504 69.0416 TD
[(the)-390.5(inclusion)-391.4(criteria)-387(for)-389.1(an)-389.3(ocriplasmin)-390.2(injection)-387.1(were)-387.7(gi-)]TJ
0 -1.1174 TD
[(ven.)-434.1(Consequently,)-429(all)-430.9(patients)-431.8(were)-433.8(informed)-426(in)-428.5(advance)]TJ
0 -1.1116 TD
[(that)-397.5(they)-397.4(were)-399.2(scheduled)-399.2(for)-400.7(vitreoretinal)-398.5(surgery)-400.3(if)-394(expe-)]TJ
T*
[(riencing)-339.7(ocriplasmin)-338.4(treatment)-337.5(failure.)]TJ
1.0137 -1.1116 TD
[(Eighty-six)-311.9(percent)-305(wanted)-309.4(to)-307.6(try)-308.7(an)-308.6(ocriplasmin)-309.6(injection)]TJ
-1.0137 -1.1174 TD
[(rst,)-272.5(due)-269.4(to)-267.3(the)-269.5(prospect)-270.2(of)-267.1(not)-268.4(having)-272.9(to)-267.3(undergo)-268(surgery)-267.8(in)]TJ
0 -1.1116 TD
[(successful)-296.2(cases.)-294.3(The)-287.9(baseline)-294.6(characteristics)-294.3(of)-290.1(the)-286.8(patients)]TJ
T*
[(who)-511(decided)-512.4(against)-511.2(the)-511.4(IOI)-511(\(14%\))-507.6(were)-514.4(comparable)-512.3(to)]TJ
0 -1.1174 TD
[(those)-334.9(who)-338.2(had)-332.8(opted)-335.1(for)-331.5(it)-336.5(\(data)-336.2(not)-331.7(shown\).)]TJ
1.0137 -1.1116 TD
[(BCVA)-543.9(testing)-544.7(and)-540.1(OCT)-542.1(\(Spectralis)]TJ
/F6 1 Tf
7.3823 0 0 6.5614 474.1227 630.8786 Tm
()Tj
/F5 1 Tf
9.843 0 0 9.843 480.6424 626.5132 Tm
[(;)-542.6(Heidelberg)-545.5(En-)]TJ
-17.0257 -1.1116 TD
[(ginee)-8(ring,)-353.5(Heidelberg,)-358.9(Germany\))-358.8(were)-358.9(performed)-359(to)-359.4(assess)]TJ
0 -1.1174 TD
[(visual)-290.1(and)-280.9(morphological)-289(outcomes,)-280.7(including)-287.9(VMT)-282.7(release)]TJ
0 -1.1116 TD
[(and)-338.5(FTMH)-335.5(closure)-332.5(over)-333.8(time.)]TJ
1.0137 -1.1116 TD
[(Da)13(ta)-274.2(ap)13.9(pe)13.9(rt)15(ai)13.8(nin)19.6(g)-277.6(t)0(o)-267.3(the)-263.8(pa)13.9(tie)18.3(nt)14.9(s)-277.4(w)0(e)13(r)0(e)-274(r)0(e)14(t)0(r)15(i)0(e)13.8(ved)-263.6(fro)19.8(m)-278.8(t)0(h)15(e)0(i)13.8(r)]TJ
-1.0137 -1.1116 TD
[(ele)17.3(ct)13.8(ron)19.8(ic)-418.2(re)14(co)13.9(rds)-412(an)13.9(d)-421.6(fro)19.8(m)-422.8(the)-413.5(OC)13.2(T)-422.7(d)0(a)13.9(t)0(a)13.8(bas)18.8(e)-422.7(ent)18.4(ri)15(es)-417.9(tha)18.4(t)]TJ
0 -1.1174 TD
[(wer)17.7(e)-480.3(l)0(i)14.8(n)0(k)15.1(e)0(d)-469.9(t)0(o)-474.6(t)0(h)15(e)-474.6(cor)18.6(re)14(spo)19.9(ndi)19.6(ng)-468.7(vis)19.8(its)19.7(.)-475.7(M)0(e)13(asu)18.8(rem)17.4(en)13.9(ts)-468.7(of)]TJ
0 -1.1116 TD
[(BCV)16.8(A)-359.1(w)0(e)13(r)0(e)-348.9(per)18.6(fo)15.1(rme)17.4(d)-358.2(i)0(n)-347.9(S)0(n)15.2(ell)18.3(en)13.9(,)-360.5(w)0(h)14.2(e)0(n)-348.9(n)0(e)13.9(ces)17.6(sa)14.1(ry;)-343.2(BCV)16.8(A)]TJ
T*
[(was)-218.3(de)13.9(te)13.8(rm)13.9(ine)18.4(d)-231.5(o)0(n)-215.3(a)-232.6(lo)15(ga)13.9(ri)15(thm)18.4(ic)-222.4(sc)14.1(al)13.8(e)-226.9(and)-217.6(co)13.9(nv)15.1(ert)18.5(ed)-222.2(to)-221.2(Ea)12.7(rl)15(y)]TJ
0 -1.1174 TD
[(Tre)17.4(at)13.8(me)12.7(nt)-296.1(Di)14.1(ab)13.9(et)13.8(ic)-297.2(Re)12.9(ti)14.8(no)15.1(pa)13.9(thy)-285.7(Stu)19.8(dy)-295.9(\(E)13.9(TD)13(RS)14.2(\))-300.6(l)0(e)13.8(t)0(t)14.8(ers)18.8(;)-300.7(a)0(n)13.9(d)]TJ
0 -1.1116 TD
[(con)18.6(ve)13.9(rsi)19.8(on)-474.5(be)13.9(tw)14.1(ee)12.8(n)-479.1(dif)19.6(fe)14(ren)18.6(t)-479.3(n)0(o)15.1(tat)18.3(io)15(ns)-474.3(wa)13(s)-479(p)0(e)13.9(rfo)19.8(rm)13.9(ed)-475.7(re)14(-)]TJ
T*
[(gar)18.6(din)19.6(g)-329.4(t)0(h)15(e)-324.8(ra)13.9(nge)18.6(s)-329.2(o)0(f)-319(v)0(i)14.9(s)0(i)15.1(o)0(n)-319(los)19.8(s)-329.2(d)0(e)13.9()0(n)15.2(e)0(d)-320.1(i)0(n)-319.1(ICD)17.9(-9)15.1(-CM)17.8(.)]TJ
1.0137 -1.1174 TD
[(We)-437.6(used)-437.4(the)-436.6(central)-437.6(retinal)-436.6(thickness)-438.3(scan)-438.5(and)-430.7(directly)]TJ
-1.0137 -1.1116 TD
[(measured)-266.7(with)-259(the)-258(measuring)-261(tool)-258.1(of)-255.6(the)-258(Spectralis)-262.2(Software)]TJ
T*
[(\(Spectralis;)-327.8(Heidelberg)-326.6(Engineering\))-328(on)-319(a)-319(micrometer)-328.2(scale)]TJ
0 -1.1174 TD
[(the)-332.9(size)-335(of)-324.7(VMT)-334.6(and)-327(the)-332.9(MH)-332.3(in)]TJ
/F7 1 Tf
13.5468 0 TD
(m)Tj
/F5 1 Tf
.5529 0 TD
[(m;)-326.1(no)-330.5(further)-331.5(calculation)]TJ
-14.0998 -1.1116 TD
[(of)-336.2(adherence)-338.2(or)-336.2(lesion)-330.4(size)-340.7(was)-333.5(performed.)]TJ
1.0137 -1.1116 TD
[(Regarding)-451.1(the)-448.1(macular)-450.3(subretinal)-451.2(deposits)-453.3(\()-81.7(MSDs\),)-448.1(we)]TJ
-1.0137 -1.1116 TD
[(registered)-406.2(clinically)-406.8(as)-400.6(well)-404.1(as)-400.6(in)-399.7(the)-402(OCT)-398.1(images)-401.8(if)-405.5(sub-)]TJ
0 -1.1174 TD
[(retinal)-350.2(deposits)-349.7(were)-347.4(present)-344(at)-349.1(the)-344.4(different)-346.5(time)-346.9(points)-346.5(of)]TJ
0 -1.1116 TD
[(our)-337.3(follow-up)-333.5(period;)-337.4(no)-330.5(specic)-339.3(analysis)-333.5(was)-339.2(performed.)]TJ
1.0137 -1.1116 TD
[(The)-622(Shapiro-Wilk)-621.6(test)-621.9(conrmed)-622.7(that)-616.4(our)-619.6(data)-623.1(were)]TJ
-1.0137 -1.1174 TD
[(normally)-310.9(distributed.)-305(Numerical)-309.5(data)-306.4(are)-305.1(presented)-307(as)-302.7(mean)]TJ
0 -1.1116 TD
[(value)-8(s)-237(and)-240.6(standard)-247.2(deviations.)-241.6(Data)-243.9(were)-243.7(analyzed)-244(by)-244.1(using)]TJ
T*
(Students)Tj
/F10 1 Tf
4.0318 0 TD
(t)Tj
/F5 1 Tf
.2765 0 TD
[(-test.)-246.3(A)]TJ
/F10 1 Tf
3.1909 0 TD
(P)Tj
/F5 1 Tf
.8582 0 TD
(value)Tj
/F6 1 Tf
2.4191 0 TD
(<)Tj
/F5 1 Tf
.5529 0 TD
[(0.05)-242.9(was)-247.1(considered)-250.6(statistically)]TJ
-11.3293 -1.1174 TD
[(signicant.)-304.8(We)-293.6(used)-299.1(the)-298.3(Point-biserial)-300.2(correlation)-298.1(\(a)-297.1(special)]TJ
0 -1.1116 TD
[(case)-243.8(of)-238.3(Pearso)-8.5(ns)-239.2(correlation\))-241.6(to)-238.5(screen)-246(for)-239.4(interrelationships)]TJ
T*
[(betwe)-8.8(en)-366.2(1)-369.7(continuous)-375.1(and)-373.1(1)-369.7(nominal)-373.2(variable)-369.6(with)-374.2(2)-369.7(cate-)]TJ
T*
[(gories.)-420(The)-414.6(Chi-square)-423.2(test)-414.6(for)-417.9(association)-418.8(was)-419.8(applied)-413.5(to)]TJ
0 -1.1174 TD
[(test)-351.2(whether)-356.6(2)-346.7(categorical)-352.4(variables)-353.3(are)-351.2(associated.)-358.8(All)-350(sta-)]TJ
0 -1.1116 TD
[(tistical)-622.1(evaluations)-614.8(were)-618.1(performed)-618.1(by)-618.5(using)-610.2(the)-620.9(SPSS)]TJ
T*
[(softwa)-8.5(re)-331.6(package)-334.9(V.23)-335.9(\(SPSS,)-336.6(Inc.,)-333.8(Chicago,)-337.2(IL\).)]TJ
/F3 1 Tf
9.9626 0 0 9.9626 313.0582 260.7307 Tm
[(Resu)-10.9(lts)]TJ
/F5 1 Tf
9.843 0 0 9.843 323.0361 242.8724 Tm
[(During)-330.1(the)-327.1(study)-328(period,)-333.8(a)-324.8(single)-330.4(intravitreal)-334.1(injection)-329.5(of)]TJ
-1.0137 -1.1116 TD
[(ocriplasmin)-292.3(was)-287.4(administered)-294.6(to)-284.5(51)-284.4(eyes)-288.8(of)-284.4(51)-284.4(patients)-293.6(who)]TJ
0 -1.1174 TD
[(met)-374.5(the)-373.2(inclusion)-374.1(criteria.)-373.2(The)-374.3(mean)-370.8(follow-up)-373.8(period)-370.7(was)]TJ
0 -1.1116 TD
(24)Tj
/F6 1 Tf
1.1692 0 TD
()Tj
/F5 1 Tf
.72 0 TD
[(14)-330.5(months)-336.1(\(range:)-338.4(648)-332.7(months\),)-334.8(and)-332.8(the)-332.9(mean)-336.3(age)-333.9(of)]TJ
-1.8892 -1.1116 TD
[(the)-327.1(patients)-322.4(was)-321.9(76)]TJ
/F6 1 Tf
8.0406 0 TD
()Tj
/F5 1 Tf
.72 0 TD
[(8)-323.6(years)-324.4(\(range:)-321.1(5094)-322.3(years\).)-323.1(About)-323.3(a)]TJ
-8.7605 -1.1174 TD
[(quarter)-252(of)-244.1(patients)-247.5(\(27.4%\))-241.4(were)-249.5(pseudophakic)-247(at)-245.4(the)-246.5(time)-243.2(of)]TJ
0 -1.1116 TD
[(inclus)-7.8(ion)-331.7(\(Table)-332.8(1\).)]TJ
1.0137 -1.1116 TD
[(The)-449.2(mean)-445.7(duration)-447.9(of)-439.9(symptoms)-448.8(was)-448.6(7.5)]TJ
/F6 1 Tf
17.6708 0 TD
()Tj
/F5 1 Tf
.7142 0 TD
[(1.9)-449.1(months.)]TJ
-19.3987 -1.1116 TD
[(The)-305.2(mean)-307.5(adhesion)-304.8(size)-306.2(before)-308.4(injection)-306.5(was)-304.6(345)]TJ
/F6 1 Tf
20.2914 0 TD
()Tj
/F5 1 Tf
.72 0 TD
(146)Tj
/F7 1 Tf
1.6703 0 TD
(m)Tj
/F5 1 Tf
.5529 0 TD
(m;)Tj
-23.2347 -1.1174 TD
[(the)-350.2(maximum)-346.8(adhesion)-345.1(size)-346.5(of)-347.8(the)-344.4(VMT)-346.1(in)-347.9(our)-343.1(patient)-344.5(co-)]TJ
0 -1.1116 TD
[(hort,)-301.7(however,)-302.3(did)-297.2(not)-297.2(exceed)-299.2(800)]TJ
/F7 1 Tf
14.071 0 TD
(m)Tj
/F5 1 Tf
.5529 0 TD
[(m)-301.8(\(Table)-298.2(1\).)-299.3(An)-296.8(FTMH)]TJ
-14.6239 -1.1116 TD
[(was)-310.4(present)-309.4(in)-301.8(21)-307.5(instances)-307(\(41%\))-306(with)-305(a)-307.5(mean)-307.5(hole)-305.2(size)-306.2(of)]TJ
0 -1.1174 TD
(263)Tj
/F6 1 Tf
1.6703 0 TD
()Tj
/F5 1 Tf
.72 0 TD
(110)Tj
/F7 1 Tf
1.6646 0 TD
(m)Tj
/F5 1 Tf
.5529 0 TD
[(m.)-351.3(The)-351.2(mean)-353.5(time)-352.6(to)-353.7(complete)-353.6(release)-357.8(of)-353.5(VMT)]TJ
-4.6078 -1.1116 TD
[(was)-327.7(12.5)]TJ
/F6 1 Tf
3.7956 0 TD
()Tj
/F5 1 Tf
.72 0 TD
[(19.9)-317.8(\(2115\))-324.4(days)-327.9(\()]TJ
/F10 1 Tf
8.0521 0 TD
(n)Tj
/F6 1 Tf
.6624 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
[(34,)-322.4(67%\))-322.2(after)-330.4(successful)]TJ
-13.95 -1.1116 TD
[(IOI.)-278.2(The)-276.4(success)-275.6(rate)-277.5(in)-273(eyes)-277.2(with)-276.2(VMT)-277(and)-275.2(without)-273.9(FTMH)]TJ
0 -1.1174 TD
[(was)-293.1(70%)-286.6(\(21of)-287.7(30)-290.2(eyes\).)-287.5(In)-290.1(eyes)-288.8(complicated)-294.9(by)-284.4(an)-285.6(FTMH,)]TJ
0 -1.1116 TD
[(the)-482.7(success)-482.9(rate)-484.9(was)-477.4(62%)-482.4(\(13)-475.6(of)-480.2(21)-480.3(eyes\).)-483.3(Interestingly,)]TJ
T*
[(despit)-7.8(e)-474.6(complete)-474.6(release)-478.8(of)-474.5(VMT)-478.6(in)-468.9(13)-474.5(of)-474.5(21)-474.5(eyes)-478.8(with)]TJ
0 -1.1174 TD
[(VMT)-300(and)-304(FTMH,)-298.6(complete)-301.8(hole)-299.4(closure)-297.9(was)-304.6(only)-298.3(achieved)]TJ
/F3 1 Tf
8.9663 0 0 8.9663 62.022 749.6502 Tm
(2)Tj
48.0541 0 TD
[(ZANDI)-333.8(ET)-338.7(AL.)]TJ
ET
endstream
endobj
37 0 obj
<>stream
/GS1 gs
BT
/F5 1 Tf
9.843 0 0 9.843 59.7543 479.2251 Tm
0 0 0 rg
0 Tc
0 Tw
[(in)-307.6(6)-306.4(cases)-308.1(\(29%)-304.9(of)-301.7(all)-310(eyes)-306(with)-305(FTMH\))-307.8(\(Table)-304(2\).)-305.1(PPV,)-306.8(in)]TJ
0 -1.1116 TD
[(combination)-574.8(with)-570(cataract)-573.5(surgery)-567.3(in)-572.5(phakic)-567.8(cases,)-570.7(was)]TJ
0 -1.1174 TD
[(performed)-399.3(in)-388.2(15)-393.9(eyes)-398.2(with)-391.4(persisting)-392.3(VMT.)-395.6(In)-393.8(addition,)-393.9(4)]TJ
0 -1.1116 TD
[(eyes)-467.3(without)-464(full)-459.6(closure)-465(of)-462.9(FTMH)-468(despite)-465.1(VMT)-461.3(release)]TJ
T*
[(after)-382.3(Jetrea)-378.6(injection)-375.6(also)-374.1(underwent)-381.8(PPV)-372.5(surgery.)-380.7(Two)-374(of)]TJ
0 -1.1174 TD
[(the)-338.7(21)-330.5(patients)-339.6(who)-332.5(required)-333.7(PPV)-337.9(decided)-333.9(against)-338.4(surgery.)]TJ
1.0137 -1.1116 TD
[(Th)13.9(e)-267.2(m)0(e)18.4(a)0(n)-256.8(B)0(C)13(V)0(A)-257.4(\()0(l)15(o)0(g)15.1(a)0(r)14(i)0(t)14.8(h)0(m)-256.9(o)0(f)-255.6(t)0(h)15(e)-267.2(mi)19.5(ni)15(ma)12.7(l)-266.2(a)0(n)19.7(g)0(l)14.9(e)-267.2(of)-255.6(re)14(so)15.3(-)]TJ
-1.0137 -1.1116 TD
[(lu)15(ti)14.8(on)-238.3([l)15(og)15.1(MA)13.3(R])14.1(\))-248.7(i)0(m)19.5(p)0(r)15.1(o)0(v)15.1(e)0(d)-239.5(f)0(r)15.1(o)0(m)-239.6(0)0(.)12.7(4)0(1)]TJ
/F6 1 Tf
15.3842 0 TD
()Tj
/F5 1 Tf
.7084 0 TD
[(0.)18.5(03)-244.1(be)19.7(fo)15.1(re)-245.2(in)20.7(je)13.8(ct)13.8(io)14.9(n)]TJ
-16.0926 -1.1116 TD
[(to)-347.9(0.)12.7(32)]TJ
/F6 1 Tf
3.0181 0 TD
()Tj
/F5 1 Tf
.7084 0 TD
[(0.)18.5(03)-347.8(at)-349.1(1)-352.4(m)0(o)13.9(n)0(t)14.9(h)-358.2(\()]TJ
/F10 1 Tf
7.2227 0 TD
(n)Tj
/F6 1 Tf
.6566 0 TD
(=)Tj
/F5 1 Tf
.7142 0 TD
[(51)15.1(,)]TJ
/F10 1 Tf
1.5897 0 TD
(P)Tj
/F6 1 Tf
.7718 0 TD
(=)Tj
/F5 1 Tf
.7084 0 TD
[(0.)12.7(05)15.1(\),)-344.3(0.)12.8(23)]TJ
/F6 1 Tf
4.5386 0 TD
()Tj
/F5 1 Tf
.7084 0 TD
[(0.)18.5(05)-347.8(at)-349.1(6)]TJ
-20.637 -1.1174 TD
[(mo)13.8(nt)14.9(hs)-249.7(\()]TJ
/F10 1 Tf
3.4961 0 TD
(n)Tj
/F6 1 Tf
.6566 0 TD
(=)Tj
/F5 1 Tf
.7142 0 TD
[(27)15.1(,)]TJ
/F10 1 Tf
1.4918 0 TD
(P)Tj
/F6 1 Tf
.7718 0 TD
(=)Tj
/F5 1 Tf
.7142 0 TD
[(0.)18.5(00)15.1(05)15.1(\),)-252.2(0.)12.7(24)]TJ
/F6 1 Tf
5.4199 0 TD
()Tj
/F5 1 Tf
.7142 0 TD
[(0.)18.5(05)-255.6(at)-251.2(12)-249.9(mo)13.9(nt)14.9(hs)-249.7(\()]TJ
/F10 1 Tf
7.7122 0 TD
(n)Tj
/F6 1 Tf
.6566 0 TD
(=)Tj
/F5 1 Tf
.7142 0 TD
[(32)15.1(,)]TJ
/F10 1 Tf
-23.0619 -1.1116 TD
(P)Tj
/F6 1 Tf
.7776 0 TD
(=)Tj
/F5 1 Tf
.7084 0 TD
[(0.)12.7(00)20.8(1\))15.1(,)-383.6(a)0(n)13.9(d)-387(0.)18.5(24)]TJ
/F6 1 Tf
6.8713 0 TD
()Tj
/F5 1 Tf
.7084 0 TD
[(0.)12.7(06)-376.6(at)-377.9(24)-376.6(mo)19.6(nt)14.9(hs)-376.4(\()]TJ
/F10 1 Tf
8.2133 0 TD
(n)Tj
/F6 1 Tf
.6566 0 TD
(=)Tj
/F5 1 Tf
.7142 0 TD
[(27)20.8(,)]TJ
/F10 1 Tf
1.6185 0 TD
(P)Tj
/F6 1 Tf
.7718 0 TD
(=)Tj
/F5 1 Tf
.7084 0 TD
[(0.)12.7(00)15.1(3\))]TJ
-21.7486 -1.1116 TD
[(af)14(te)13.8(r)-214.2(i)0(n)15(j)0(e)13.8(c)0(t)13.8(i)0(o)15(n)-214.2(\(F)15.3(ig)15(.)-210.8(1)0(\))15.1(.)-216.5(Th)13.9(e)-215.4(S)0(u)15.2(p)0(p)15.1(l)0(e)19.6(m)0(e)12.7(n)0(t)14.9(a)0(r)14(y)-214.2(Fi)15.1(g.)-206.1(S1)-203.6(de)13.9(pi)15(ct)13.8(s)-214(t)0(h)15(e)]TJ
0 -1.1174 TD
[(me)12.7(an)-251(BC)13(VA)-251.6(\(l)15(og)15.1(MA)19.1(R\))-250.9(fo)15.1(r)-260.3(a)0(l)13.8(l)-254.7(ti)14.8(me)12.7(po)15.1(in)15(ts)-249.8(of)-249.8(al)13.8(l)-260.4(p)0(a)19.7(t)0(i)14.8(e)0(n)13.9(t)0(s)-249.8(w)0(h)14.2(o)]TJ
0 -1.1116 TD
[(co)13.9(mp)13.8(le)13.8(te)13.8(d)-260.3(2)0(4)-255.6(m)0(o)19.6(n)0(t)15(h)0(s)-255.4(o)0(f)-255.6(f)0(o)15.1(l)0(l)14.8(o)0(w)14.2(-)0(u)15.1(p)-260.3(\()]TJ
/F10 1 Tf
14.3705 0 TD
(n)Tj
/F6 1 Tf
.6624 0 TD
(=)Tj
/F5 1 Tf
.7084 0 TD
[(27)15.1(\).)]TJ
-14.7276 -1.1116 TD
[(In)-203.8(patients)-207.2(with)-207.1(successful)-209.9(release)-208.1(of)-209.5(the)-200.4(VMT)-207.9(and)-206.1(without)]TJ
-1.0137 -1.1174 TD
[(persistent)-307.1(MH,)-306.9(the)-298.3(mean)-307.5(BCVA)-302(\(logMAR\))-305.4(before)-302.6(injection)]TJ
0 -1.1116 TD
[(was)-517.8(0.37)]TJ
/F6 1 Tf
3.9857 0 TD
()Tj
/F5 1 Tf
.72 0 TD
[(0.05)-507.8(and)-517.1(improved)-512.4(to)-514.9(0.26)]TJ
/F6 1 Tf
11.7901 0 TD
()Tj
/F5 1 Tf
.72 0 TD
[(0.05)-507.8(at)-516.1(1)-513.7(month)]TJ
-17.2158 -1.1116 TD
(\()Tj
/F10 1 Tf
.3341 0 TD
(n)Tj
/F6 1 Tf
.6681 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
(30,)Tj
/F10 1 Tf
1.5551 0 TD
(P)Tj
/F6 1 Tf
.7776 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
[(0.05\),)-305(0.29)]TJ
/F6 1 Tf
4.5559 0 TD
()Tj
/F5 1 Tf
.7142 0 TD
[(0.08)-306.2(at)-303(3)-306.4(months)-301.5(\()]TJ
/F10 1 Tf
7.4761 0 TD
(n)Tj
/F6 1 Tf
.6681 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
(12,)Tj
/F10 1 Tf
1.5494 0 TD
(P)Tj
/F6 1 Tf
.7833 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
(0.27\),)Tj
-21.9618 -1.1174 TD
(0.20)Tj
/F6 1 Tf
1.918 0 TD
()Tj
/F5 1 Tf
.72 0 TD
[(0.06)-294.7(at)-297.2(6)-294.8(months)-295.8(\()]TJ
/F10 1 Tf
7.4415 0 TD
(n)Tj
/F6 1 Tf
.6681 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
(15,)Tj
/F10 1 Tf
1.5436 0 TD
(P)Tj
/F6 1 Tf
.7833 0 TD
(=)Tj
/F5 1 Tf
.7142 0 TD
[(0.01\),)-299.2(and)-298.2(0.21)]TJ
/F6 1 Tf
6.2896 0 TD
()Tj
/F5 1 Tf
.72 0 TD
[(0.05)-294.7(at)]TJ
-21.5183 -1.1116 TD
[(12)-209.5(months)-203.6(\()]TJ
/F10 1 Tf
4.6942 0 TD
(n)Tj
/F6 1 Tf
.6681 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
(23,)Tj
/F10 1 Tf
1.4514 0 TD
(P)Tj
/F6 1 Tf
.7833 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
[(0.005\))-204.7(after)-203.7(injection.)-212(Patients)-207(without)]TJ
-9.037 -1.1116 TD
[(successful)-319.3(release)-323.3(of)-313.2(the)-315.6(VMT)-317.3(or)-313.2(with)-316.6(persistent)-318.6(MH)-315(had)-315.5(a)]TJ
T*
[(baseline)-306.1(BCVA)-302(of)-295.9(0.45)]TJ
/F6 1 Tf
9.7109 0 TD
()Tj
/F5 1 Tf
.72 0 TD
[(0.03)-300.5(\()]TJ
/F10 1 Tf
2.3845 0 TD
(n)Tj
/F6 1 Tf
.6624 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
[(21\))-302.8(before)-296.9(injection)-306.5(with)]TJ
-14.1977 -1.1174 TD
[(no)-428.4(improvement)-431.8(seen)-427(1)-427.3(month)-427.3(after)-428.4(ocriplasmin)-430.5(injection)]TJ
0 -1.1116 TD
[(\(visual)-279.6(acuity)-279.9(0.43)]TJ
/F6 1 Tf
7.6546 0 TD
()Tj
/F5 1 Tf
.72 0 TD
(0.04,)Tj
/F10 1 Tf
2.2751 0 TD
(n)Tj
/F6 1 Tf
.6681 0 TD
(=)Tj
/F5 1 Tf
9.843 0 0 9.843 178.2425 227.1684 Tm
(21,)Tj
/F10 1 Tf
1.5263 0 TD
(P)Tj
/F6 1 Tf
.7776 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
[(0.62\).)-276.2(One)-276(month)-277.6(after)]TJ
-15.0616 -1.1116 TD
[(PPV,)-364.4(however,)-365.7(the)-367.5(BCVA)-365.3(improved)-362.6(to)-365.2(0.34)]TJ
/F6 1 Tf
18.4944 0 TD
()Tj
/F5 1 Tf
.72 0 TD
[(0.11)-358.1(\()]TJ
/F10 1 Tf
2.4421 0 TD
(n)Tj
/F6 1 Tf
.6681 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
(14,)Tj
/F10 1 Tf
-23.0446 -1.1174 TD
(P)Tj
/F6 1 Tf
.7833 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
[(0.20\).)-362.6(Further)-365.9(improvement)-362.7(was)-368(evident)-361.6(3)-364(\(0.29)]TJ
/F6 1 Tf
20.0726 0 TD
()Tj
/F5 1 Tf
.72 0 TD
(0.07,)Tj
/F10 1 Tf
-22.2958 -1.1116 TD
(n)Tj
/F6 1 Tf
.6681 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
(14,)Tj
/F10 1 Tf
1.7394 0 TD
(P)Tj
/F6 1 Tf
.7833 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
[(0.02\),)-489.3(6)-490.7(\(0.37)]TJ
/F6 1 Tf
6.065 0 TD
()Tj
/F5 1 Tf
.72 0 TD
(0.11,)Tj
/F10 1 Tf
2.4882 0 TD
(n)Tj
/F6 1 Tf
.6681 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
(11,)Tj
/F10 1 Tf
1.7394 0 TD
(P)Tj
/F6 1 Tf
.7776 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
[(0.34\),)-495.1(and)-488.3(12)]TJ
-18.529 -1.1116 TD
[(months)-284.2(\(0.35)]TJ
/F6 1 Tf
5.4832 0 TD
()Tj
/F5 1 Tf
.7142 0 TD
(0.11,)Tj
/F10 1 Tf
2.2808 0 TD
(n)Tj
/F6 1 Tf
.6681 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
(8,)Tj
/F10 1 Tf
1.031 0 TD
(P)Tj
/F6 1 Tf
.7776 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
[(0.22\))-284.3(after)-278.6(PPV)-280.3(surgery.)]TJ
14.1286 55.0455 TD
[(The)-483.7(nonstatistical)-485.8(difference)-488(in)-486.1(baseline)-484.7(BCVA)-486.3(of)-486(pa-)]TJ
-1.0137 -1.1174 TD
[(tients)-526.3(without)-533.1(need)-530.9(of)-526.3(vitrectomy)-533.3(\()]TJ
/F10 1 Tf
15.2978 0 TD
(n)Tj
/F6 1 Tf
.6624 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
[(30\))-527.4(versus)-531.5(unsuc-)]TJ
-16.6801 -1.1116 TD
[(cessful)-366.8(\()]TJ
/F10 1 Tf
3.4731 0 TD
(n)Tj
/F6 1 Tf
.6681 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
[(21\))-360.4(release)-369.4(of)-359.3(the)-367.5(VMT)-363.4(or)-359.3(persistent)-370.4(MH)-361.1(after)]TJ
-4.8612 -1.1116 TD
[(IOI)-608.9(with)-604.5(the)-609.4(need)-605.7(of)-606.9(PPV)-608.6(\(0.37)]TJ
/F6 1 Tf
14.837 0 TD
()Tj
/F5 1 Tf
.72 0 TD
[(0.05)-605.7(vs.)-604.4(0.45)]TJ
/F6 1 Tf
6.0131 0 TD
()Tj
/F5 1 Tf
.72 0 TD
(0.03,)Tj
/F10 1 Tf
-22.2901 -1.1116 TD
(P)Tj
/F6 1 Tf
.7776 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
[(0.55\))-272.8(may)-270.6(be)-268.3(explained)-272.9(by)-272.9(the)-269.5(percentage)-276.1(of)-267.1(eyes)-271.5(with)-276.2(a)]TJ
-1.4975 -1.1174 TD
[(concomitant)-334(MH)-338(\(23.3%)-332.5(vs.66.7%\).)]TJ
1.0137 -1.1116 TD
[(Forty-one)-258.7(percent)-264.7(of)-261.4(patients)-264.8(needed)-269.3(a)-261.4(vitrectomy)-262.6(in)-261.5(spite)]TJ
-1.0137 -1.1116 TD
[(of)-474.5(prior)-472.1(IOI.)-479.8(The)-472.2(mean)-480.3(time)-473.6(to)-474.6(vitrectomy)-481.5(was)-471.7(1.9)]TJ
/F6 1 Tf
22.3189 0 TD
()Tj
/F5 1 Tf
.72 0 TD
(0.7)Tj
-23.0388 -1.1174 TD
[(months)-330.3(\(Suppl)-6.6(ementary)-336.2(Fig.)-329.3(S2\).)]TJ
1.0137 -1.1116 TD
[(The)-466.4(patients)-472.1(without)-469.8(release)-473(of)-468.7(VMT)-472.8(and/or)-468.6(persistent)]TJ
-1.0137 -1.1116 TD
[(MH)-292(after)-295.9(IOI)-292.1(who)-292.2(underwent)-295.4(PPV)-291.8(showed)-290.7(an)-297.1(improvement)]TJ
0 -1.1174 TD
[(of)-319(BCVA)-330.8(over)-322.3(12)-324.7(months)-318.8(after)-330.4(vitrectomy)-326(that)-322.6(was)-327.7(similar)]TJ
0 -1.1116 TD
[(to)-463.1(the)-465.4(patients)-472.1(with)-466.3(successful)-469(release)-467.3(of)-468.7(VMT)-467.1(after)-468.7(IOI)]TJ
T*
[(\(Supplementary)-538.6(Fig.)-536.6(S2\).)-536.4(There)-538.9(were)-537.5(no)-537.8(adverse)-535.1(events)]TJ
T*
[(other)-312(than)-316.7(2)-312.1(patients)-310.8(with)-316.6(transient)-317.7(intraocular)-315.4(pressure)-316(rise)]TJ
0 -1.1174 TD
[(shortly)-457(after)-462.9(PPV)-458.9(that)-460.8(could)-456.1(be)-458.4(controlled)-463(medically)-464.3(and)]TJ
0 -1.1116 TD
[(disappeared)-339.2(by)-330.5(1)-335.2(month)-335.2(after)-336.2(surgery.)]TJ
1.0137 -1.1116 TD
[(Floaters)-252.9(were)-261(reported)-258.9(by)-255.6(all)-252.4(51)-255.6(patients)-259(after)-255.6(ocriplasmin)]TJ
-1.0137 -1.1174 TD
[(injection;)-457.5(however,)-457.8(these)-462.8(disappeared)-460.2(within)-457.1(2448)-166.8(h.)-459.5(No)]TJ
0 -1.1116 TD
[(ocriplasmin)-419(drug-related)-414.3(complications,)-420.2(including)-420.4(lens)-414.4(de-)]TJ
T*
[(stabilization,)-258(phacodonesis,)-256(dyschromatopsia,)-260.7(retinal)-258.1(tear,)-257.9(or)]TJ
0 -1.1174 TD
[(retinal)-223.5(detachment,)-227.9(were)-220.7(observed)-224(over)-224.4(the)-223.5(48-month)-223.3(period.)]TJ
0 -1.1116 TD
[(One)-270.3(phakic)-274(patient)-269.6(required)-276.1(cataract)-274(surgery)-273.6(after)-272.8(4)-271.8(years.)]TJ
1.0137 -1.1116 TD
[(MSDs)-397.5(were)-399.2(evident)-402(in)-399.7(23)-393.9(eyes)-404(\(45%\))-398.2(after)-399.6(ocriplasmin)]TJ
-1.0137 -1.1174 TD
[(injection;)-278.9(of)-272.9(these,)-281.9(61%)-275.1(resolved)-276(within)-278.6(12)-272.9(months)-278.5(\(Table)-275.2(2)]TJ
0 -1.1116 TD
[(and)-211.8(Fig.)-219.8(2\).)-213(This)-218.6(was)-212.5(comparable)-224.3(in)-215.4(eyes)-213.9(with)-218.6(VMT)-213.6(with)-218.6(and)]TJ
T*
[(without)-204.8(FTMH.)-206.5(Complete)-209.5(resolution)-208.2(of)-203.8(the)-206.2(deposits)-211.4(occurred)]TJ
T*
[(within)-307.4(3)-306.4(months)-313(in)-307.6(50%)-303.9(of)-307.4(eyes)-311.8(with)-310.8(VMT)-311.5(and)-304(FTHM)-312.5(and)]TJ
0 -1.1174 TD
[(within)-307.4(1)-306.4(year)-306.2(in)-307.6(the)-309.9(other)-306.3(50%,)-307.3(with)-310.8(a)-307.5(similar)-309.8(mean)-307.5(FTHM)]TJ
0 -1.1116 TD
[(size)-369.5(of)-365(172)]TJ
/F7 1 Tf
4.7921 0 TD
(m)Tj
/F5 1 Tf
.5529 0 TD
[(m)-365.2(compared)-370.6(with)-368.4(196)]TJ
/F7 1 Tf
9.2846 0 TD
(m)Tj
/F5 1 Tf
.5529 0 TD
[(m.)-362.9(In)-370.8(eyes)-363.6(with)-368.4(VMT)]TJ
-15.1826 -1.1116 TD
[(without)-176(FMTH,)-177.7(56%)-177.2(showed)-175.5(resolution)-179.4(of)-175(the)-177.4(deposits)-176.9(within)]TJ
0 -1.1174 TD
[(3)-415.8(months,)-420.2(22%)-419.1(within)-416.8(6)-415.8(months,)-420.2(and)-419.2(22%)-419.1(within)-416.8(1)-421.6(year.)]TJ
0 -1.1116 TD
[(Symptoms)-385.4(improved)-385.7(in)-388.2(response)-385.1(to)-388.2(VMT)-386.4(resolution)-386.7(in)-388.2(all)]TJ
T*
[(cases)-486.7(independent)-482.4(of)-480.2(the)-488.4(presence)-485.5(of)-480.2(subretinal)-485.8(deposits.)]TJ
0 -1.1174 TD
[(There)-176(was)-177.9(no)-175(statistical)-177.3(difference)-182.7(in)-175.1(BCVA)-175.3(\(logMAR\))-178.7(at)-176.3(any)]TJ
0 -1.1116 TD
[(time)-191.4(point)-190.1(between)-196.5(eyes)-196.6(with)-189.8(and)-194.5(without)-193.3(subretinal)-192.1(deposits.)]TJ
1.0137 -1.1116 TD
[(Further,)-329(we)-326.8(screened)-335.8(our)-325.8(data)-335.2(regarding)-329.1(potential)-329.5(factors)]TJ
-1.0137 -1.1116 TD
[(predicting)-238.3(success)-235.2(or)-238.3(failure.)-238.3(Success)-235.3(was)-241.3(dened)-233.4(as)-239.3(a)-232.6(vision)]TJ
0 -1.1174 TD
[(gain)-305.2(of)-307.4(more)-306.3(than)-305.2(5)-306.4(ETDRS)-303.4(letters)-309.7(and)-309.7(resolution)-306.1(of)-307.4(VMT.)]TJ
0 -1.1116 TD
[(Interestingly,)-325.6(neither)-327(the)-327.1(size)-323.4(of)-324.7(the)-327.1(VMT)-323.1(and)-327(the)-327.1(MH,)-324.2(nor)]TJ
T*
[(the)-235(presence)-237.9(of)-232.6(MSDs)-236.2(seemed)-235.8(to)-232.7(play)-236.1(a)-232.6(role)-236.1(in)-232.7(the)-235(success)-241(of)]TJ
0 -1.1174 TD
[(VMT)-409.5(resolution.)-413.2(Regarding)-410.8(the)-413.5(presence)-410.7(of)-411.1(MSD,)-411.5(neither)]TJ
0 -1.1116 TD
[(the)-379(VMT)-386.4(size)-386.8(nor)-377.7(the)-384.7(presence)-387.6(of)-382.3(an)-383.5(MH)-384.1(and)-378.8(its)-383.5(size)-386.8(did)]TJ
T*
[(affect)-459.4(the)-453.8(visual)-457.1(outcome)-454.9(after)-457.2(IOI)-459.1(at)-452.8(the)-459.6(measured)-456.8(time)]TJ
0 -1.1174 TD
[(points)-335(\(Supplementary)-337(Table)-337.5(S1\).)]TJ
1.0137 -1.1116 TD
[(Further,)-334.8(we)-338.3(tried)-335.2(to)-336.4(identify)-338.6(potential)-335.3(risk)-338.4(factors)-338.2(for)-337.3(the)]TJ
-1.0137 -1.1116 TD
[(development)-207.2(of)-203.8(subretinal)-203.6(macular)-208.4(deposits.)-203.4(Interestingly,)-210.4(no)]TJ
0 -1.1174 TD
[(correlation)-263.6(was)-258.6(found)-258.9(between)-259.9(age)-259.1(and)-257.9(gender)-262.3(regarding)-260(the)]TJ
0 -1.1116 TD
[(appearance)-363.5(of)-365(MSDs;)-364.2(in)-359.4(addition,)-365.1(MHs)-362(and)-361.6(MSDs)-362.9(did)-360.5(not)]TJ
T*
[(show)-287.3(a)-290.2(correlation.)-295.8(However,)-291.7(VMT)-288.5(and)-292.4(MSD)-287.1(did)-291.4(correlate:)]TJ
/F10 1 Tf
T*
(r)Tj
/F5 1 Tf
7.3823 0 0 6.5614 314.6456 175.5779 Tm
(pb)Tj
/F6 1 Tf
9.843 0 0 9.843 323.6598 177.222 Tm
(=)Tj
/F5 1 Tf
.72 0 TD
(0.39**,)Tj
/F10 1 Tf
3.3521 0 TD
(P)Tj
/F6 1 Tf
.7833 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
[(0.005)-353.4(as)-360.3(did)-354.8(VMT)-351.9(and)-355.8(age:)]TJ
/F10 1 Tf
11.8362 0 TD
(r)Tj
/F5 1 Tf
7.3823 0 0 6.5614 498.8408 175.5779 Tm
(pb)Tj
/F6 1 Tf
9.843 0 0 9.843 507.9117 177.222 Tm
.1622 Tc
(=-)Tj
/F5 1 Tf
1.2671 0 TD
0 Tc
(0.36**,)Tj
/F10 1 Tf
-21.2879 -1.1174 TD
(P)Tj
/F6 1 Tf
.7776 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
[(0.009,)-351.1(in)-342.1(the)-350.2(sense)-347.3(that)-351.4(with)-345.4(age)-351.2(a)-347.8(VMT)-346.1(resolution)-352.2(be-)]TJ
-1.4975 -1.1116 TD
[(comes)-291.1(less)-287.5(likely)-290.4(and)-292.4(in)-290.3(the)-286.8(case)-295.7(of)-284.4(VMT)-294.3(resolution)-288.8(the)-292.6(de-)]TJ
T*
[(velopment)-272.9(of)-267.1(MSD)-275.6(might)-271.9(increase.)]TJ
1.0137 -1.1174 TD
[(We)-362.7(used)-368.2(the)-367.5(Point-biserial)-369.3(correlation)-373(\(a)-366.2(special)-368.4(case)-370.6(of)]TJ
-1.0137 -1.1116 TD
[(Pearsons)-213.2(correlation\))-212.8(to)-203.9(screen)-211.5(for)-210.6(a)-209.6(correlation)-211.8(between)-213.8(age)]TJ
T*
[(and)-200.3(MSD)-200.7(and)-206.1(could)-202.6(not)-199.3(nd)-199(any:)]TJ
/F10 1 Tf
13.2531 0 TD
(r)Tj
/F5 1 Tf
7.3823 0 0 6.5614 445.0392 109.8141 Tm
(pb)Tj
/F6 1 Tf
9.843 0 0 9.843 454.1101 111.4582 Tm
(=)Tj
/F5 1 Tf
.72 0 TD
(\()Tj
/F6 1 Tf
.3341 0 TD
(-)Tj
/F5 1 Tf
.5472 0 TD
(0.38\),)Tj
/F10 1 Tf
2.5343 0 TD
(P)Tj
/F6 1 Tf
.7833 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
[(0.086.)-201.3(We)]TJ
-20.1935 -1.1174 TD
[(then)-253.4(used)-253(the)-252.3(Chi-square)-250.4(test)-253.3(for)-250.9(association)-257.5(between)-254.1(gender)]TJ
0 -1.1116 TD
[(and)-373.1(MSD:)]TJ
/F10 1 Tf
4.625 0 TD
(P)Tj
/F6 1 Tf
.7833 0 TD
(=)Tj
/F5 1 Tf
.72 0 TD
[(0.55)-369.6(and)-373.1(could)-375.4(not)-366.3(nd)-371.8(an)-372(association.)-376.1(We,)]TJ
-6.1283 -1.1116 TD
[(therefore,)-362.5(concluded)-364.9(that)-362.9(gender)-360.2(and)-361.6(age)-362.7(are)-356.9(not)-360.5(playing)-360.5(a)]TJ
0 -1.1174 TD
[(role)-218.8(in)-215.4(developing)-215.2(MSD;)-219.3(however,)-215.9(age)-218.7(does)-218.5(play)-218.8(a)-215.4(role)-218.8(in)-215.4(the)]TJ
0 -1.1116 TD
[(likelihood)-179.7(of)-180.7(resolution)-179.4(of)-180.7(VMT)-179.1(and)-183(its)-176.2(resolution)-185.1(plays)-179.4(a)-180.8(role)]TJ
T*
[(in)-267.3(the)-275.3(development)-270.5(of)-272.9(MSDs.)]TJ
ET
59.754 122.627 239.131 .22675 re
f
59.754 46.261 239.131 .22675 re
f
BT
/F9 1 Tf
9.845 0 0 9.845 74.7212 148.1953 Tm
(Table)Tj
/F5 1 Tf
3.0002 0 TD
(2.)Tj
/F9 1 Tf
1.2496 0 TD
[(Clinical)-338.5(Characteristics)-333.4(of)-331.2(Patients)]TJ
-3.674 -1.0077 TD
[(with)-334.7(Symptomatic)-336(Vitreomacular)-332.2(Adhesion)]TJ
.9329 -1.0135 TD
[(Treated)-336(with)-334.7(Intravitreal)-335.2(Ocriplasmin)]TJ
/F5 1 Tf
-3.029 -1.6181 TD
[(Mean)-335.4(vitreomacular)-341.7(adhesion)]TJ
.9962 -1.0135 TD
[(duration)-331.9(after)-335.7(intravitreal)]TJ
T*
[(ocriplasmin)-331.5(injection)-340.2(\(days\))]TJ
12.5133 2.027 TD
(12.5)Tj
/F6 1 Tf
1.9176 0 TD
()Tj
/F5 1 Tf
.7141 0 TD
[(19.9)-334.6(\(Range)-337.5(2115\))]TJ
-16.1412 -3.0348 TD
[(Macular)-339.7(subretinal)-335.1(deposits)]TJ
.9962 -1.0135 TD
(present,)Tj
/F10 1 Tf
3.4782 0 TD
(n)Tj
/F5 1 Tf
.8292 0 TD
(\(%\))Tj
12.0929 1.0135 TD
[(23)-336(\(45\))]TJ
-17.3966 -2.027 TD
[(VMT)-339.8(resolution,)]TJ
/F10 1 Tf
7.1464 0 TD
(n)Tj
/F5 1 Tf
.835 0 TD
[(\(%\))-7916.2(34)-336(\(67\))]TJ
-7.9813 -1.0135 TD
[(MH)-337.6(closure,)]TJ
/F10 1 Tf
5.4188 0 TD
(n)Tj
/F5 1 Tf
.835 0 TD
[(\(%\))-10144.8(6)-335(\(29\))]TJ
ET
59.754 699.534 239.131 .28345 re
f
59.754 553.436 239.131 .22675 re
f
BT
/F9 1 Tf
9.845 0 0 9.845 74.211 725.1588 Tm
(Table)Tj
/F5 1 Tf
3.0002 0 TD
(1.)Tj
/F9 1 Tf
1.2496 0 TD
[(Baseline)-338.1(Characteristics)-333.4(of)-331.2(Patients)]TJ
-3.6221 -1.0135 TD
[(with)-334.7(Symptomatic)-336(Vitreomacular)-332.2(Adhesion)]TJ
.9329 -1.0135 TD
[(Treated)-336(with)-334.7(Intravitreal)-335.2(Ocriplasmin)]TJ
/F5 1 Tf
-3.029 -1.6182 TD
[(Mean)-335.4(age)-339.3(\(years\))-6349.3(76)]TJ
/F6 1 Tf
14.644 0 TD
()Tj
/F5 1 Tf
.7198 0 TD
[(8)-329.2(\(Range:)-338.7(5094\))]TJ
-15.3638 -1.0135 TD
[(Gender)-337.3(\(F/M\))-11200.4(32/19)]TJ
0 -1.0077 TD
[(No.)-334.4(of)-336(eyes)-334.4(\()]TJ
/F10 1 Tf
5.4188 0 TD
(n)Tj
/F5 1 Tf
.835 0 TD
(eyes)Tj
/F6 1 Tf
1.9464 0 TD
(=)Tj
/F10 1 Tf
.7198 0 TD
(n)Tj
/F5 1 Tf
-7.9238 -1.0135 TD
(patients\))Tj
12.4788 1.0135 TD
[(51)-336(\(30)-331.2(Isolated)-338.7(VMT\))]TJ
-13.475 -2.027 TD
[(Mean)-335.4(follow-up)-338.3(time)]TJ
.9962 -1.0135 TD
(\(months\))Tj
12.4788 1.0135 TD
(24)Tj
/F6 1 Tf
1.169 0 TD
()Tj
/F5 1 Tf
.7198 0 TD
[(14)-330.2(\(Range:)-338.7(648\))]TJ
-15.3638 -2.0212 TD
[(Mean)-335.4(logMAR)-337(BCVA)]TJ
.9962 -1.0135 TD
[(\(Snellen)-332.9(equivalent\))]TJ
10.7282 1.0135 TD
(0.41)Tj
/F6 1 Tf
1.9176 0 TD
()Tj
/F5 1 Tf
.7198 0 TD
[(0.03)-334.6(\(Range:)-332.9(0.100.92\))]TJ
-14.3618 -2.027 TD
(Pseudophakic,)Tj
/F10 1 Tf
6.1501 0 TD
(n)Tj
/F5 1 Tf
.8292 0 TD
[(\(%\))-7657.1(14)-330.2(\(27.4\))]TJ
-6.9794 -1.0077 TD
[(Mean)-335.4(vitreomacular)]TJ
.9962 -1.0135 TD
[(adhesion)-332.7(size)-334.5(\()]TJ
/F7 1 Tf
6.1213 0 TD
(m)Tj
/F5 1 Tf
.5528 0 TD
(m\))Tj
4.8084 1.0135 TD
(345)Tj
/F6 1 Tf
1.6642 0 TD
()Tj
/F5 1 Tf
.7198 0 TD
[(146)-331.2(\(Range:)-338.7(80798\))]TJ
-14.8628 -2.027 TD
[(MH)-337.6(present,)]TJ
/F10 1 Tf
5.4188 0 TD
(n)Tj
/F5 1 Tf
.835 0 TD
[(\(%\))-8757(21)-330.2(\(41\))]TJ
-6.2538 -1.0135 TD
[(Mean)-335.4(MH)-337.6(aperture)]TJ
.9962 -1.0077 TD
[(diameter)-335.4(\()]TJ
/F7 1 Tf
4.1865 0 TD
(m)Tj
/F5 1 Tf
.5528 0 TD
(m\))Tj
6.7433 1.0077 TD
(263)Tj
/F6 1 Tf
1.6642 0 TD
()Tj
/F5 1 Tf
.7198 0 TD
[(110)-331.2(\(Range:)-338.7(50400\))]TJ
8.7511 0 0 8.7511 67.748 541.6439 Tm
[(BCVA,)-622.9(best-corrected)-622.5(visual)-618.5(acuity;)-625.3(F,)-616.8(female;)-623.9(FTMH,)-621.9(full)]TJ
-.9134 -1.0236 TD
[(thickness)-251.7(macular)-249.4(hole;)-245.5(logMAR,)-249(logarithm)-242.2(of)-248.9(the)-249.1(minimal)-243.5(angle)-247.9(of)]TJ
T*
[(resolution;)-647.5(M,)-646.6(male;)-645.9(MH,)-641.2(macular)-651(hole;)-640.7(VMT,)-649.1(vitreomacular)]TJ
0 -1.0301 TD
(traction.)Tj
/F3 1 Tf
8.9663 0 0 8.9663 59.7543 749.7069 Tm
[(OCRIPLASMIN)-340.6(FOR)-334(VITREOMACULAR)-342(TRACTION)-30069.3(3)]TJ
ET
endstream
endobj
42 0 obj
<>stream
q
1 i
227.679 732.245 m
552.189 732.245 l
552.189 430.129 l
227.679 430.129 l
W n
/GS1 gs
q
324.929 0 0 302.116 227.679 430.129 cm
/Im1 Do
Q
Q
/GS1 gs
BT
/F8 1 Tf
9.845 0 0 9.845 62.022 617.5558 Tm
0 0 0 rg
0 Tc
0 Tw
[(FIG.)-451.9(1.)]TJ
/F5 1 Tf
4.2325 0 TD
[(BCVA)-451(in)-451.3(logMAR:)-447.6(before)]TJ
-4.2325 -1.0135 TD
[(the)-332.6(rst)-332(injection)-334.4(of)-330.2(ocriplasmin)-331.5(\(Pre-)]TJ
T*
[(Injection\))-271.9(and)-274.8(1)-265.9(day,)-272.4(1)-271.6(week,)-275.4(and)-269(1,)-269.3(3,)]TJ
0 -1.0077 TD
[(6,)-349.9(12,)-345.1(and)-349.7(24)-347.5(months)-352.6(later,)-350.8(*)]TJ
/F10 1 Tf
12.0296 0 TD
(P)Tj
/F6 1 Tf
.7774 0 TD
()Tj
/F5 1 Tf
.7198 0 TD
(0.05.)Tj
-13.5268 -1.0135 TD
[(Error)-305.6(bars)-304.4(represent)-306.1(the)-303.8(SEM.)-307.6(BCVA,)]TJ
T*
[(best-corrected)-307.8(visual)-301(acuity;)-303.5(logMAR,)]TJ
T*
[(logarithm)-639.5(of)-641.2(the)-637.8(minimal)-644.4(angle)-640.9(of)]TJ
0 -1.0077 TD
[(resolution;)-306.3(SEM,)-307.6(standard)-309.7(error)-305.6(of)-307.2(the)]TJ
0 -1.0135 TD
(mean.)Tj
ET
q
1 i
192.019 357.449 m
552.132 357.449 l
552.132 46.545 l
192.019 46.545 l
W n
q
360.113 0 0 310.904 192.019 46.545 cm
/Im2 Do
Q
Q
BT
/F8 1 Tf
9.845 0 0 9.845 62.022 328.1385 Tm
[(FIG.)-492.2(2.)]TJ
/F5 1 Tf
4.2728 0 TD
[(Re)18.9(pr)21(es)14.3(en)19.9(ta)19.7(ti)20.7(ve)-412(im)19.7(-)]TJ
-4.2728 -1.0135 TD
[(ag)19.9(es)-751.6(of)-756.4(ma)18.7(cu)19.9(la)19.7(r)-761.1(s)0(u)21.2(b)0(r)15.3(e)0(t)19.7(i)0(n)20.9(a)0(l)]TJ
0 -1.0077 TD
[(de)19.9(po)21.1(si)15.3(t)-461.9(r)0(e)14.1(s)0(o)21.2(l)0(u)20.9(t)0(i)20.7(o)0(n)-456.9(o)0(v)21.1(e)0(r)-458.1(t)0(i)20.7(m)0(e)18.7(.)]TJ
0 -1.0135 TD
[(Th)19.9(e)]TJ
/F10 1 Tf
1.7333 0 TD
[(bo)21.1(x)]TJ
/F5 1 Tf
1.6182 0 TD
[(ap)14.1(pe)19.9(ar)19.9(s)-190.9(a)0(u)19.9(t)0(o)20.9(m)0(a)18.7(t)0(i)14.9(c)0(a)18.7(l)0(l)20.7(y)]TJ
-3.3515 -1.0135 TD
[(wh)20.2(en)-769(me)18.7(as)14.3(ur)21.1(in)20.9(g)-778.4(w)0(i)20.1(t)0(h)-773.8(S)0(D)20.4(-)]TJ
T*
[(OC)19.2(T)-174.9(a)0(n)14.1(d)-173.7(sh)21.2(ow)20.2(s)-179.3(t)0(h)20.9(e)-180.7(ar)19.9(ea)-165.6(th)20.9(at)-170.3(is)]TJ
0 -1.0077 TD
[(me)18.7(as)20(ur)15.3(ed)19.9(.)]TJ
/F8 1 Tf
4.5493 0 TD
[(\(A)20.2(\))]TJ
/F5 1 Tf
1.8946 0 TD
[(SD)20.4(-O)14.5(CT)-522.4(im)19.7(-)]TJ
-6.4438 -1.0135 TD
[(ag)19.9(es)-699.8(at)-700.1(pr)15.3(es)20.1(en)19.9(ta)19.7(ti)20.7(on)-698.8(be)14.1(fo)21(re)]TJ
T*
[(oc)19.9(ri)20.9(pl)15.1(as)20.1(mi)19.7(n)-1135.4(i)0(n)20.9(j)0(e)19.7(c)0(t)13.9(i)0(o)20.9(n)0(.)]TJ
/F8 1 Tf
10.5957 0 TD
[(\(B)20.1(\))]TJ
/F5 1 Tf
-10.5957 -1.0135 TD
[(SD)20.4(-O)14.5(CT)-464.8(i)16.1(m)20.9(a)15.1(g)0(e)25.6(s)-467.3(a)15.1(t)-467.6(1)-467.4(m)15.1(o)16.3(n)16.3(t)16.1(h)]TJ
0 -1.0077 TD
-.016 Tc
[(post-)-16(o)10.8(c)-.9(riplasmin)-212.8(i).1(njection)-16(.)]TJ
/F8 1 Tf
10.5209 0 TD
0 Tc
(\(C\))Tj
/F5 1 Tf
-10.5209 -1.0135 TD
[(SD-OCT)-326.3(images)-320.4(at)-320(6)-323.5(months)]TJ
T*
-.016 Tc
[(post-)-16(o)10.8(c)-.9(riplasmin)-224.3(i).1(njection.)]TJ
/F8 1 Tf
10.5439 0 TD
0 Tc
[(\(D)20.2(\))]TJ
/F5 1 Tf
-10.5439 -1.0077 TD
[(SD)20.4(-O)14.5(CT)-228.7(im)19.7(ag)19.9(es)-227.6(at)-227.9(12)-232.3(m)15.1(o)0(n)15.3(t)0(h)20.9(s)]TJ
0 -1.0135 TD
[(po)21.1(st)15.3(-o)21(cr)19.9(ip)20.9(la)19.7(sm)20.1(in)-1631.8(in)20.9(je)19.7(ct)19.7(io)20.9(n.)]TJ
T*
[(Th)19.9(e)]TJ
/F10 1 Tf
1.8715 0 TD
[(ar)21.2(ro)21.2(w)]TJ
/F5 1 Tf
2.7238 0 TD
[(is)-313(po)21.1(in)15.1(ti)20.7(ng)-312.9(to)15.1(wa)19.1(rd)]TJ
-4.5953 -1.0135 TD
-.0208 Tc
[(t)-20.8(h).1(e)-201.5(s)-20.8(u)-5.3(b)-20.8(re)-20.8(ti)-20.8(na)-20.8(l)-191.1(d)-20.8(e)-6.7(p)-20.8(os)-20.8(it)-20.8(s)]TJ
/F8 1 Tf
8.8278 0 TD
0 Tc
[(\(E)14.3(\))]TJ
/F5 1 Tf
1.4972 0 TD
[(SD)20.4(-)]TJ
-10.3251 -1.0077 TD
[(OC)19.2(T)-635.6(i)0(m)19.7(a)0(g)19.9(e)0(s)-619.1(a)0(t)-625.3(2)0(4)-623.9(m)15.1(on)15.3(th)20.9(s)]TJ
0 -1.0135 TD
[(po)21.1(st)15.3(-o)21(cr)19.9(ip)20.9(la)19.7(sm)20.1(in)-1631.8(in)20.9(je)19.7(ct)19.7(io)20.9(n.)]TJ
/F8 1 Tf
T*
[(\(F)19.9(\))]TJ
/F5 1 Tf
1.9061 0 TD
[(SD)14.6(-O)20.2(CT)-637.6(im)19.7(ag)19.9(es)-642.2(at)-636.8(36)]TJ
-1.9061 -1.0135 TD
[(mo)19.9(nt)20.9(hs)-652.5(po)15.3(st)21(-o)21(cr)19.9(ip)20.9(la)13.9(sm)20.1(in)-652.9(in)20.9(-)]TJ
0 -1.0077 TD
[(je)19.7(ct)19.7(io)15.1(n)]TJ
/F8 1 Tf
2.862 0 TD
[(\(G)19.9(\))]TJ
/F5 1 Tf
1.6124 0 TD
[(SD)20.4(-O)20.2(CT)-176.9(im)19.7(ag)19.9(es)-175.7(at)]TJ
-4.4744 -1.0135 TD
[(48)-704.5(mo)19.9(nt)20.9(hs)-704.4(po)15.3(st)21(-o)21(cr)19.9(ip)15.1(la)19.7(sm)20.1(in)]TJ
T*
[(inject)-8.8(ion)-648.1(and)-649.1(after)-652.4(catara)-10.8(ct)]TJ
T*
[(surgery)-7.9(.)-832.6(SD-OCT)-9.6(,)-826.8(spectra)-10.4(l)]TJ
0 -1.0077 TD
[(domai)-7.5(n-optic)-8.5(al)-308.5(cohere)-9.5(nce)-310.5(to-)]TJ
0 -1.0135 TD
[(mogra)-7.3(phy.)]TJ
/F3 1 Tf
8.9663 0 0 8.9663 304.611 27.6094 Tm
(4)Tj
ET
endstream
endobj
44 0 obj
<>stream
Adobe d C
v
s !1AQa"q2B#R3b$r%C4Scs5D'6Tdt&
EFVU(eufv7GWgw8HXhx)9IYiy*:JZjz ? Nlٳd/P[X&/ZHE7#L%"
vݙFsx^q